Cardiac channelopathies in pediatric patients - 7-years single center experience.

Abstract

INTRODUCTION:

Channelopathies are associated with mutations of genes encoding proteins creating or interacting with the specialized ion channels in myocardial cell membranes, thus forming arrhythmogenic substrate predisposing the patient to sudden cardiac death. The study focuses the clinical and ECG presentation and management of children with channelopathies in Slovakia.

SUBJECT AND METHODS:

Twenty-two children with suspected channelopathy were admitted to Children's Cardiac Center Bratislava in the years 2007-2014. Genetic testing was made in 19 patients.

RESULTS:

Fourteen patients were symptomatic. Long QT syndrome was genetically proven in eight and catecholaminergic polymorphic ventricular tachycardia in five patients. Twenty children are treated with beta-blockers, five in combination with mexiletine or flecainide. Nine patients received implantable cardiac defibrillator and one underwent left cardiac sympathetic denervation.

CONCLUSION:

Both clinical presentation and genetic testing must be considered in the diagnostic and therapeutic process of channelopathies. Early diagnosis allows for adequate treatment and lifestyle modification.

• Authors: V Illikova, P Hlivak, R Hatala
• Journal: Journal of electrocardiology (J Electrocardiol) 2015 Mar-Apr Vol. 48 Issue 2 Pg. 150-6 ISSN: 1532-8430 [Electronic] United States
• PMID: 25554238 (Publication Type: Journal Article)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Adrenergic beta-Antagonists
• Anti-Arrhythmia Agents
• Mexiletine
• Flecainide

Topics

• Adolescent
• Adrenergic beta-Antagonists (therapeutic use)
• Anti-Arrhythmia Agents (therapeutic use)
• Cardiac Surgical Procedures
• Channelopathies (diagnosis, genetics, therapy)
• Child
• Child, Preschool
• Death, Sudden, Cardiac
• Defibrillators, Implantable
• Drug Therapy, Combination
• Electrocardiography
• Electrocardiography, Ambulatory
• Female
• Flecainide (therapeutic use)
• Genetic Testing
• Genotype
• Humans
• Infant
• Infant, Newborn
• Male
• Mexiletine (therapeutic use)
• Phenotype
• Risk Factors